PPARγ signaling and emerging opportunities for improved therapeutics

Pharmacological Research

Volumn 111, Issue , 2016, Pages 76-85

  Wang, Shuibang ^a   Dougherty, Edward J ^a   Danner, Robert L ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

E1A binding protein p300 (EP300); G protein coupled receptor 40 (GPR40); P38 mitogen activated protein kinase (p38 MAPK); Peroxisome proliferator activated receptor gamma (PPARy); PPARy co activator 1alpha (PGC 1); Thiazolidinediones (TZDs)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLIN DEPENDENT KINASE 5; G PROTEIN COUPLED RECEPTOR 40; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; UNSATURATED FATTY ACID; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; FATTY ACID; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT RESPIRATORY DISTRESS SYNDROME; ATHEROSCLEROSIS; BLADDER CANCER; BONE DENSITY; BROWN ADIPOSE TISSUE; CONGESTIVE HEART FAILURE; DRUG TARGETING; ENDOTHELIUM; FLUID RETENTION; FRACTURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; NITRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PULMONARY HYPERTENSION; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN; AGONISTS; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION;

ANIMALS; CARDIOVASCULAR AGENTS; DRUG DESIGN; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84973896878     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.02.028     Document Type: Review

References (138)

1. L. Chen, D.J. Magliano, and P.Z. Zimmet The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives Nat. Rev. Endocrinol. 8 4 2012 228 236
2. H. Yki-Jarvinen Thiazolidinediones N. Engl. J. Med. 351 11 2004 1106 1118
3. T. Sohda, K. Mizuno, E. Imamiya, Y. Sugiyama, T. Fujita, and Y. Kawamatsu Studies on antidiabetic agents II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives Chem. Pharm. Bull. (Tokyo) 30 10 1982 3580 3600
4. T. Fujita, Y. Sugiyama, S. Taketomi, T. Sohda, Y. Kawamatsu, H. Iwatsuka, and Z. Suzuoki Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent Diabetes 32 9 1983 804 810
5. T. Fujiwara, S. Yoshioka, T. Yoshioka, I. Ushiyama, and H. Horikoshi Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats Diabetes 37 11 1988 1549 1558
6. T. Sohda, Y. Momose, K. Meguro, Y. Kawamatsu, Y. Sugiyama, and H. Ikeda Studies on antidiabetic agents synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones Arzneimittelforschung 40 1 1990 37 42
7. N.D. Oakes, C.J. Kennedy, A.B. Jenkins, D.R. Laybutt, D.J. Chisholm, and E.W. Kraegen A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat Diabetes 43 10 1994 1203 1210
8. B.C. Cantello, M.A. Cawthorne, G.P. Cottam, P.T. Duff, D. Haigh, R.M. Hindley, C.A. Lister, S.A. Smith, and P.L. Thurlby [Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents J. Med. Chem. 37 23 1994 3977 3985
9. P.B. Watkins, and R.W. Whitcomb Hepatic dysfunction associated with troglitazone N. Engl. J. Med. 338 13 1998 916 917
10. F. Lalloyer, and B. Staels Fibrates, glitazones, and peroxisome proliferator-activated receptors Arterioscler. Thromb. Vasc. Biol. 30 5 2010 894 899
11. A. Ciudin, C. Hernandez, and R. Simo Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology Curr. Top. Med. Chem. 12 6 2012 585 604
12. S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 10 2007 1189 1195
13. P. Shah, and S. Mudaliar Pioglitazone: side effect and safety profile Expert Opin. Drug Saf. 9 2 2010 347 354
14. J.D. Lewis, L.A. Habel, C.P. Quesenberry, B.L. Strom, T. Peng, M.M. Hedderson, S.F. Ehrlich, R. Mamtani, W. Bilker, D.J. Vaughn, L. Nessel, S.K. Van Den Eeden, and A. Ferrara Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes JAMA 314 3 2015 265 277
15. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 6294 1990 645 650
16. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 5 1992 879 887
17. T. Sher, H.F. Yi, O.W. McBride, and F.J. Gonzalez cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor Biochemistry 32 21 1993 5598 5604
18. A. Schmidt, N. Endo, S.J. Rutledge, R. Vogel, D. Shinar, and G.A. Rodan Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids Mol. Endocrinol. 6 10 1992 1634 1641
19. J.S. Qi, V. Desai-Yajnik, M.E. Greene, B.M. Raaka, and H.H. Samuels The ligand-binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing, and transactivation Mol. Cell. Biol. 15 3 1995 1817 1825
20. M. Ahmadian, J.M. Suh, N. Hah, C. Liddle, A.R. Atkins, M. Downes, and R.M. Evans PPAR gamma signaling and metabolism: the good, the bad and the future Nat. Med. 19 5 2013 557 566
21. A. Ptasinska, S. Wang, J. Zhang, R.A. Wesley, and R.L. Danner Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway FASEB J. 21 3 2007 950 961
22. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor Cell 79 7 1994 1147 1156
23. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 270 22 1995 12953 12956
24. B.M. Forman, P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 83 5 1995 803 812
25. S. Schwartz, P. Raskin, V. Fonseca, and J.F. Graveline Effect of troglitazone in insulin-treated patients with type II diabetes mellitus: troglitazone and Exogenous Insulin Study Group N. Engl. J. Med. 338 13 1998 861 866
26. S.E. Inzucchi, D.G. Maggs, G.R. Spollett, S.L. Page, F.S. Rife, V. Walton, and G.I. Shulman Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus N. Engl. J. Med. 338 13 1998 867 872
27. L.C. Bell-Parikh, T. Ide, J.A. Lawson, P. McNamara, M. Reilly, and G.A. FitzGerald Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPAR gamma J. Clin. Invest. 112 6 2003 945 955
28. S.A. Kliewer, S.S. Sundseth, S.A. Jones, P.J. Brown, G.B. Wisely, C.S. Koble, P. Devchand, W. Wahli, T.M. Willson, J.M. Lenhard, and J.M. Lehmann Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma Proc. Natl. Acad. Sci. U.S.A. 94 9 1997 4318 4323
29. T.M. Larsen, S. Toubro, and A. Astrup PPAR gamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27 2 2003 147 161
30. L. Nagy, P. Tontonoz, J.G. Alvarez, H. Chen, and R.M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma Cell 93 2 1998 229 240
31. P. Raskin, M. Rendell, M.C. Riddle, J.F. Dole, M.I. Freed, J. Rosenstock, and Rosiglitazone Clinical Trials Study Group A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes Diabetes Care 24 7 2001 1226 1232
32. S. Aronoff, S. Rosenblatt, S. Braithwaite, J.W. Egan, A.L. Mathisen, and R.L. Schneider Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group Diabetes Care 23 11 2000 1605 1611
33. D. Glintborg, M. Andersen, C. Hagen, L. Heickendorff, and A.P. Hermann Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial J. Clin. Endocrinol. Metab. 93 5 2008 1696 1701
34. K.K. Ryan, B. Li, B.E. Grayson, E.K. Matter, S.C. Woods, and R.J. Seeley A role for central nervous system PPAR-gamma in the regulation of energy balance Nat. Med. 17 5 2011 623 626
35. M. Lu, D.A. Sarruf, S. Talukdar, S. Sharma, P. Li, G. Bandyopadhyay, S. Nalbandian, W. Fan, J.R. Gayen, S.K. Mahata, N.J. Webster, M.W. Schwartz, and J.M. Olefsky Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones Nat. Med. 17 5 2011 618 622
36. Y. Guan, C. Hao, D.R. Cha, R. Rao, W. Lu, D.E. Kohan, M.A. Magnuson, R. Redha, Y. Zhang, and M.D. Breyer Thiazolidinediones expand body fluid volume through PPAR gamma stimulation of ENaC-mediated renal salt absorption Nat. Med. 11 8 2005 861 866
37. E. Borsting, V.P. Cheng, C.K. Glass, V. Vallon, and R. Cunard Peroxisome proliferator-activated receptor-gamma agonists repress epithelial sodium channel expression in the kidney Am. J. Physiol. Renal Physiol. 302 5 2012 F540 551
38. Y. Wan, L.W. Chong, and R.M. Evans PPAR-gamma regulates osteoclastogenesis in mice Nat. Med. 13 12 2007 1496 1503
39. A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, and R.L. Jilka Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 3 2005 1226 1235
40. W. Wei, X. Wang, M. Yang, L.C. Smith, P.C. Dechow, J. Sonoda, R.M. Evans, and Y. Wan PGC1 beta mediates PPAR gamma activation of osteoclastogenesis and rosiglitazone-induced bone loss Cell Metab. 11 6 2010 503 516
41. B.M. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor Diabetes 47 4 1998 507 514
42. M. Li, G. Pascual, and C.K. Glass Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene Mol. Cell. Biol. 20 13 2000 4699 4707
43. G. Pascual, A.L. Fong, S. Ogawa, A. Gamliel, A.C. Li, V. Perissi, D.W. Rose, T.M. Willson, M.G. Rosenfeld, and C.K. Glass A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 7059 2005 759 763
44. P. Ketsawatsomkron, C.J. Pelham, S. Groh, H.L. Keen, F.M. Faraci, and C.D. Sigmund Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J. Biol. Chem. 285 13 2010 9311 9316
45. M. Auclair, C. Vigouroux, F. Boccara, E. Capel, C. Vigeral, B. Guerci, O. Lascols, J. Capeau, and M. Caron-Debarle Peroxisome proliferator-activated receptor-gamma mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system Arterioscler. Thromb. Vasc. Biol. 33 4 2013 829 838
46. R.B. Goldberg, D.M. Kendall, M.A. Deeg, J.B. Buse, A.J. Zagar, J.A. Pinaire, M.H. Tan, M.A. Khan, A.T. Perez, S.J. Jacober, and G.S. Investigators A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 7 2005 1547 1554
47. A.T. Reddy, S.P. Lakshmi, J.M. Kleinhenz, R.L. Sutliff, C.M. Hart, and R.C. Reddy Endothelial cell peroxisome proliferator-activated receptor gamma reduces endotoxemic pulmonary inflammation and injury J. Immunol. 189 11 2012 5411 5420
48. A. Qu, Y.M. Shah, S.K. Manna, and F.J. Gonzalez Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice Arterioscler. Thromb. Vasc. Biol. 32 1 2012 65 73
49. T. Seno, M. Hamaguchi, E. Ashihara, M. Kohno, H. Ishino, A. Yamamoto, M. Kadoya, K. Nakamura, K. Murakami, S. Matoba, T. Maekawa, and Y. Kawahito 15-Deoxy-delta(1)(2),(1)(4) prostaglandin J(2) reduces the formation of atherosclerotic lesions in apolipoprotein E knockout mice PLoS One 6 10 2011 e25541
50. G. Hansmann, V.A. de Jesus Perez, T.P. Alastalo, C.M. Alvira, C. Guignabert, J.M. Bekker, S. Schellong, T. Urashima, L. Wang, N.W. Morrell, and M. Rabinovitch An antiproliferative BMP-2/PPAR gamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension J. Clin. Invest. 118 5 2008 1846 1857
51. Y. Liu, X.Y. Tian, G. Mao, X. Fang, M.L. Fung, J.Y. Shyy, Y. Huang, and N. Wang Peroxisome proliferator-activated receptor-gamma ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor Hypertension 60 6 2012 1471 1478
52. I. Barroso, M. Gurnell, V.E. Crowley, M. Agostini, J.W. Schwabe, M.A. Soos, G.L. Maslen, T.D. Williams, H. Lewis, A.J. Schafer, V.K. Chatterjee, and S. O'Rahilly Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension Nature 402 6764 1999 880 883
53. M. Jain, G.R. Budinger, A. Lo, D. Urich, S.E. Rivera, A.K. Ghosh, A. Gonzalez, S.E. Chiarella, K. Marks, H.K. Donnelly, S. Soberanes, J. Varga, K.A. Radigan, N.S. Chandel, and G.M. Mutlu Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-gamma Am. J. Respir. Crit. Care Med. 183 11 2011 1490 1498
54. J.M. Kaplan, J.A. Cook, P.W. Hake, M. O'Connor, T.J. Burroughs, and B. Zingarelli 15-Deoxy-delta(12,14)-prostaglandin J(2) (15D-PGJ(2)), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock Shock 24 1 2005 59 65
55. W.T. Wu, C.C. Lee, C.J. Lee, Y.M. Subeq, R.P. Lee, and B.G. Hsu Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats Biol. Res. Nurs. 13 1 2011 38 43
56. P.R. Baker, F.J. Schopfer, V.B. O'Donnell, and B.A. Freeman Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids Free Radic. Biol. Med. 46 8 2009 989 1003
57. P.R. Baker, Y. Lin, F.J. Schopfer, S.R. Woodcock, A.L. Groeger, C. Batthyany, S. Sweeney, M.H. Long, K.E. Iles, L.M. Baker, B.P. Branchaud, Y.E. Chen, and B.A. Freeman Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands J. Biol. Chem. 280 51 2005 42464 42475
58. F.J. Schopfer, Y. Lin, P.R. Baker, T. Cui, M. Garcia-Barrio, J. Zhang, K. Chen, Y.E. Chen, and B.A. Freeman Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand Proc. Natl. Acad. Sci. U.S.A. 102 7 2005 2340 2345
59. H. Wang, H. Liu, Z. Jia, G. Guan, and T. Yang Effects of endogenous PPAR agonist nitro-oleic acid on metabolic syndrome in obese zucker rats PPAR Res. 2010 2010 601562
60. B.A. Freeman, P.R. Baker, F.J. Schopfer, S.R. Woodcock, A. Napolitano, and M. d'Ischia Nitro-fatty acid formation and signaling J. Biol. Chem. 283 23 2008 15515 15519
61. F.J. Schopfer, M.P. Cole, A.L. Groeger, C.S. Chen, N.K. Khoo, S.R. Woodcock, F. Golin-Bisello, U.N. Motanya, Y. Li, J. Zhang, M.T. Garcia-Barrio, T.K. Rudolph, V. Rudolph, G. Bonacci, P.R. Baker, H.E. Xu, C.I. Batthyany, Y.E. Chen, T.M. Hallis, and B.A. Freeman Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions J. Biol. Chem. 285 16 2010 12321 12333
62. T. Itoh, L. Fairall, K. Amin, Y. Inaba, A. Szanto, B.L. Balint, L. Nagy, K. Yamamoto, and J.W. Schwabe Structural basis for the activation of PPAR gamma by oxidized fatty acids Nat. Struct. Mol. Biol. 15 9 2008 924 931
63. A.T. Reddy, S.P. Lakshmi, and R.C. Reddy The nitrated fatty acid 10-nitro-oleate diminishes severity of LPS-induced acute lung injury in mice PPAR Res. 2012 2012 617063
64. A.T. Reddy, S.P. Lakshmi, S. Dornadula, S. Pinni, D.R. Rampa, and R.C. Reddy The nitrated fatty acid 10-nitro-oleate attenuates allergic airway disease J. Immunol. 191 5 2013 2053 2063
65. S. Borniquel, E.A. Jansson, M.P. Cole, B.A. Freeman, and J.O. Lundberg Nitrated oleic acid up-regulates PPAR gamma and attenuates experimental inflammatory bowel disease Free Radic. Biol. Med. 48 4 2010 499 505
66. A. Von Knethen, and B. Brune Activation of peroxisome proliferator-activated receptor gamma by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst J. Immunol. 169 5 2002 2619 2626
67. K. Hata, R. Nishimura, F. Ikeda, K. Yamashita, T. Matsubara, T. Nokubi, and T. Yoneda Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis Mol. Biol. Cell 14 2 2003 545 555
68. T. Maekawa, W. Jin, and S. Ishii The role of ATF-2 family transcription factors in adipocyte differentiation: antiobesity effects of p38 inhibitors Mol. Cell. Biol. 30 3 2010 613 625
69. M. Aouadi, J. Jager, K. Laurent, T. Gonzalez, M. Cormont, B. Binetruy, Y. Le Marchand-Brustel, J.F. Tanti, and F. Bost p38MAP Kinase activity is required for human primary adipocyte differentiation FEBS Lett. 581 29 2007 5591 5596
70. J.A. Engelman, A.H. Berg, R.Y. Lewis, A. Lin, M.P. Lisanti, and P.E. Scherer Constitutively active mitogen-activated protein kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis J. Biol. Chem. 274 50 1999 35630 35638
71. W. Cao, K.W. Daniel, J. Robidoux, P. Puigserver, A.V. Medvedev, X. Bai, L.M. Floering, B.M. Spiegelman, and S. Collins p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene Mol. Cell. Biol. 24 7 2004 3057 3067
72. Y. Zhang, H. Guo, J.A. Deis, M.G. Mashek, M. Zhao, D. Ariyakumar, A.G. Armien, D.A. Bernlohr, D.G. Mashek, and X. Chen Lipocalin 2 regulates brown fat activation via a nonadrenergic activation mechanism J. Biol. Chem. 289 32 2014 22063 22077
73. P. Puigserver, J. Rhee, J. Lin, Z. Wu, J.C. Yoon, C.Y. Zhang, S. Krauss, V.K. Mootha, B.B. Lowell, and B.M. Spiegelman Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPAR gamma coactivator-1 Mol. Cell 8 5 2001 971 982
74. M. Fan, J. Rhee, J. St-Pierre, C. Handschin, P. Puigserver, J. Lin, S. Jaeger, H. Erdjument-Bromage, P. Tempst, and B.M. Spiegelman Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK Genes Dev. 18 3 2004 278 289
75. T. Teruel, R. Hernandez, M. Benito, and M. Lorenzo Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes J. Biol. Chem. 278 1 2003 263 269
76. M.R. Bratton, D.E. Frigo, K.A. Vigh-Conrad, D. Fan, S. Wadsworth, J.A. McLachlan, and M.E. Burow Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase Carcinogenesis 30 1 2009 106 113
77. M. Chhikara, S. Wang, S.J. Kern, G.A. Ferreyra, J.J. Barb, P.J. Munson, and R.L. Danner Carbon monoxide blocks lipopolysaccharide-induced gene expression by interfering with proximal TLR4 to NF-kappaB signal transduction in human monocytes PLoS One 4 12 2009 e8139
78. A. Haschemi, B.Y. Chin, M. Jeitler, H. Esterbauer, O. Wagner, M. Bilban, and L.E. Otterbein Carbon monoxide induced PPAR gamma SUMOylation and UCP2 block inflammatory gene expression in macrophages PLoS One 6 10 2011 e26376
79. M. Bilban, F.H. Bach, S.L. Otterbein, E. Ifedigbo, J.C. d'Avila, H. Esterbauer, B.Y. Chin, A. Usheva, S.C. Robson, O. Wagner, and L.E. Otterbein Carbon monoxide orchestrates a protective response through PPAR gamma Immunity 24 5 2006 601 610
80. 12,14-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species J. Biol. Chem. 277 33 2002 29681 29685
81. S.Z. Duan, C.Y. Ivashchenko, M.W. Russell, D.S. Milstone, and R.M. Mortensen Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice Circ. Res. 97 4 2005 372 379
82. O.S. Gardner, C.W. Shiau, C.S. Chen, and L.M. Graves Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress J. Biol. Chem. 280 11 2005 10109 10118
83. M. Ng, T. Fleming, M. Robinson, B. Thomson, N. Graetz, C. Margono, E.C. Mullany, S. Biryukov, C. Abbafati, S.F. Abera, J.P. Abraham, N.M. Abu-Rmeileh, T. Achoki, F.S. AlBuhairan, Z.A. Alemu, R. Alfonso, M.K. Ali, R. Ali, N.A. Guzman, W. Ammar, P. Anwari, A. Banerjee, S. Barquera, S. Basu, D.A. Bennett, Z. Bhutta, J. Blore, N. Cabral, I.C. Nonato, J.C. Chang, R. Chowdhury, K.J. Courville, M.H. Criqui, D.K. Cundiff, K.C. Dabhadkar, L. Dandona, A. Davis, A. Dayama, S.D. Dharmaratne, E.L. Ding, A.M. Durrani, A. Esteghamati, F. Farzadfar, D.F. Fay, V.L. Feigin, A. Flaxman, M.H. Forouzanfar, A. Goto, M.A. Green, R. Gupta, N. Hafezi-Nejad, G.J. Hankey, H.C. Harewood, R. Havmoeller, S. Hay, L. Hernandez, A. Husseini, B.T. Idrisov, N. Ikeda, F. Islami, E. Jahangir, S.K. Jassal, S.H. Jee, M. Jeffreys, J.B. Jonas, E.K. Kabagambe, S.E. Khalifa, A.P. Kengne, Y.S. Khader, Y.H. Khang, D. Kim, R.W. Kimokoti, J.M. Kinge, Y. Kokubo, S. Kosen, G. Kwan, T. Lai, M. Leinsalu, Y. Li, X. Liang, S. Liu, G. Logroscino, P.A. Lotufo, Y. Lu, J. Ma, N.K. Mainoo, G.A. Mensah, T.R. Merriman, A.H. Mokdad, J. Moschandreas, M. Naghavi, A. Naheed, D. Nand, K.M. Narayan, E.L. Nelson, M.L. Neuhouser, M.I. Nisar, T. Ohkubo, S.O. Oti, A. Pedroza, D. Prabhakaran, N. Roy, U. Sampson, H. Seo, S.G. Sepanlou, K. Shibuya, R. Shiri, I. Shiue, G.M. Singh, J.A. Singh, V. Skirbekk, N.J. Stapelberg, L. Sturua, B.L. Sykes, M. Tobias, B.X. Tran, L. Trasande, H. Toyoshima, S. van de Vijver, T.J. Vasankari, J.L. Veerman, G. Velasquez-Melendez, V.V. Vlassov, S.E. Vollset, T. Vos, C. Wang, X. Wang, E. Weiderpass, A. Werdecker, J.L. Wright, Y.C. Yang, H. Yatsuya, J. Yoon, S.J. Yoon, Y. Zhao, M. Zhou, S. Zhu, A.D. Lopez, C.J. Murray, and E. Gakidou Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 384 9945 2014 766 781
84. A.S. Banks, F.E. McAllister, J.P. Camporez, P.J. Zushin, M.J. Jurczak, D. Laznik-Bogoslavski, G.I. Shulman, S.P. Gygi, and B.M. Spiegelman An ERK/Cdk5 axis controls the diabetogenic actions of PPAR gamma Nature 517 7534 2015 391 395
85. S. Hocking, D. Samocha-Bonet, K.L. Milner, J.R. Greenfield, and D.J. Chisholm Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots Endocr. Rev. 34 4 2013 463 500
86. X. Ma, P. Lee, D.J. Chisholm, and D.E. James Control of adipocyte differentiation in different fat depots; implications for pathophysiology or therapy Front. Endocrinol. (Lausanne) 6 2015 1
87. J.A. Kim, Y. Wei, and J.R. Sowers Role of mitochondrial dysfunction in insulin resistance Circ. Res. 102 4 2008 401 414
88. D.G. Carey, G.J. Cowin, G.J. Galloway, N.P. Jones, J.C. Richards, N. Biswas, and D.M. Doddrell Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected] Obes. Res. 10 10 2002 1008 1015
89. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, K. Cusi, L.J. Mandarino, and R.A. DeFronzo Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 6 2002 2784 2791
90. M. Adams, C.T. Montague, J.B. Prins, J.C. Holder, S.A. Smith, L. Sanders, J.E. Digby, C.P. Sewter, M.A. Lazar, V.K. Chatterjee, and S. O'Rahilly Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation J. Clin. Invest. 100 12 1997 3149 3153
91. H. Hirose, T. Kawai, Y. Yamamoto, M. Taniyama, M. Tomita, K. Matsubara, Y. Okazaki, T. Ishii, Y. Oguma, I. Takei, and T. Saruta Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes Metabolism 51 3 2002 314 317
92. K. Fujisawa, T. Nishikawa, D. Kukidome, K. Imoto, T. Yamashiro, H. Motoshima, T. Matsumura, and E. Araki TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis Biochem. Biophys. Res. Commun. 379 1 2009 43 48
93. M. Adams, M.J. Reginato, D. Shao, M.A. Lazar, and V.K. Chatterjee Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site J. Biol. Chem. 272 8 1997 5128 5132
94. E. Hu, J.B. Kim, P. Sarraf, and B.M. Spiegelman Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma Science 274 5295 1996 2100 2103
95. H.S. Camp, S.R. Tafuri, and T. Leff c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity Endocrinology 140 1 1999 392 397
96. S.M. Rangwala, B. Rhoades, J.S. Shapiro, A.S. Rich, J.K. Kim, G.I. Shulman, K.H. Kaestner, and M.A. Lazar Genetic modulation of PPAR gamma phosphorylation regulates insulin sensitivity Dev. Cell 5 4 2003 657 663
97. K. Helenius, Y. Yang, J. Alasaari, and T.P. Makela Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation Mol. Cell. Biol. 29 2 2009 315 323
98. J.H. Choi, A.S. Banks, J.L. Estall, S. Kajimura, P. Bostrom, D. Laznik, J.L. Ruas, M.J. Chalmers, T.M. Kamenecka, M. Bluher, P.R. Griffin, and B.M. Spiegelman Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR gamma by Cdk5 Nature 466 7305 2010 451 456
99. F. Picard, M. Kurtev, N. Chung, A. Topark-Ngarm, T. Senawong, R. Machado De Oliveira, M. Leid, M.W. McBurney, and L. Guarente Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma Nature 429 6993 2004 771 776
100. O. van Beekum, A.B. Brenkman, L. Grontved, N. Hamers, N.J. van den Broek, R. Berger, S. Mandrup, and E. Kalkhoven The adipogenic acetyltransferase Tip60 targets activation function 1 of peroxisome proliferator-activated receptor gamma Endocrinology 149 4 2008 1840 1849
101. L. Han, R. Zhou, J. Niu, M.A. McNutt, P. Wang, and T. Tong SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence Nucleic Acids Res. 38 21 2010 7458 7471
102. L. Qiang, L. Wang, N. Kon, W. Zhao, S. Lee, Y. Zhang, M. Rosenbaum, Y. Zhao, W. Gu, S.R. Farmer, and D. Accili Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma Cell 150 3 2012 620 632
103. D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain Genes Cells 9 11 2004 1017 1029
104. Z.E. Floyd, and J.M. Stephens Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation Obes. Res. 12 6 2004 921 928
105. P.A. Dutchak, T. Katafuchi, A.L. Bookout, J.H. Choi, R.T. Yu, D.J. Mangelsdorf, and S.A. Kliewer Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones Cell 148 3 2012 556 567
106. X.J. Yang, and S. Gregoire A recurrent phospho-sumoyl switch in transcriptional repression and beyond Mol. Cell 23 6 2006 779 786
107. G.E. Kilroy, X. Zhang, and Z.E. Floyd PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal Obesity (Silver Spring) 17 4 2009 665 673
108. C.P. Briscoe, M. Tadayyon, J.L. Andrews, W.G. Benson, J.K. Chambers, M.M. Eilert, C. Ellis, N.A. Elshourbagy, A.S. Goetz, D.T. Minnick, P.R. Murdock, H.R. Sauls Jr., U. Shabon, L.D. Spinage, J.C. Strum, P.G. Szekeres, K.B. Tan, J.M. Way, D.M. Ignar, S. Wilson, and A.I. Muir The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 278 13 2003 11303 11311
109. A.D. Mancini, and V. Poitout The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol. Metab. 24 8 2013 398 407
110. D. Gras, P. Chanez, V. Urbach, I. Vachier, P. Godard, and C. Bonnans Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor Am. J. Physiol. Lung Cell. Mol. Physiol. 296 6 2009 L970 978
111. S. Mohammad GPR40 agonists for the treatment of type 2 diabetes mellitus: benefits and challenges Curr. Drug Targets 2015
112. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa, and M. Fujino Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 Nature 422 6928 2003 173 176
113. P. Steneberg, N. Rubins, R. Bartoov-Shifman, M.D. Walker, H. Edlund, and F.F.A. The receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse Cell Metab. 1 4 2005 245 258
114. K. Nagasumi, R. Esaki, K. Iwachidow, Y. Yasuhara, K. Ogi, H. Tanaka, M. Nakata, T. Yano, K. Shimakawa, S. Taketomi, K. Takeuchi, H. Odaka, and Y. Kaisho Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice Diabetes 58 5 2009 1067 1076
115. C.P. Briscoe, A.J. Peat, S.C. McKeown, D.F. Corbett, A.S. Goetz, T.R. Littleton, D.C. McCoy, T.P. Kenakin, J.L. Andrews, C. Ammala, J.A. Fornwald, D.M. Ignar, and S. Jenkinson Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules Br. J. Pharmacol. 148 5 2006 619 628
116. R. Vettor, M. Granzotto, D. De Stefani, E. Trevellin, M. Rossato, M.G. Farina, G. Milan, C. Pilon, A. Nigro, G. Federspil, R. Vigneri, L. Vitiello, R. Rizzuto, R. Baratta, and L. Frittitta Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization J. Clin. Endocrinol. Metab. 93 9 2008 3541 3550
117. V. Poitout, and D.C. Lin Modulating GPR40: therapeutic promise and potential in diabetes Drug Discov. Today 18 23-24 2013 1301 1308
118. J. Luo, G. Swaminath, S.P. Brown, J. Zhang, Q. Guo, M. Chen, K. Nguyen, T. Tran, L. Miao, P.J. Dransfield, M. Vimolratana, J.B. Houze, S. Wong, M. Toteva, B. Shan, F. Li, R. Zhuang, and D.C. Lin A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents PLoS One 7 10 2012 e46300
119. H. Lan, L.M. Hoos, L. Liu, G. Tetzloff, W. Hu, S.J. Abbondanzo, G. Vassileva, E.L. Gustafson, J.A. Hedrick, and H.R. Davis Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease Diabetes 57 11 2008 2999 3006
120. H.E. Xu, M.H. Lambert, V.G. Montana, D.J. Parks, S.G. Blanchard, P.J. Brown, D.D. Sternbach, J.M. Lehmann, G.B. Wisely, T.M. Willson, S.A. Kliewer, and M.V. Milburn Molecular recognition of fatty acids by peroxisome proliferator-activated receptors Mol. Cell 3 3 1999 397 403
121. K. Kotarsky, N.E. Nilsson, E. Flodgren, C. Owman, and B. Olde A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs Biochem. Biophys. Res. Commun. 301 2 2003 406 410
122. N.J. Smith, L.A. Stoddart, N.M. Devine, L. Jenkins, and G. Milligan The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1 J. Biol. Chem. 284 26 2009 17527 17539
123. S.S. Choi, E.S. Kim, M. Koh, S.J. Lee, D. Lim, Y.R. Yang, H.J. Jang, K.A. Seo, S.H. Min, I.H. Lee, S.B. Park, P.G. Suh, and J.H. Choi A novel non-agonist peroxisome proliferator-activated receptor gamma (PPARgamma) ligand UHC1 blocks PPAR gamma phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity J. Biol. Chem. 289 38 2014 26618 26629
124. A.A. Amato, S. Rajagopalan, J.Z. Lin, B.M. Carvalho, A.C. Figueira, J. Lu, S.D. Ayers, M. Mottin, R.L. Silveira, P.C. Souza, R.H. Mourao, M.J. Saad, M. Togashi, L.A. Simeoni, D.S. Abdalla, M.S. Skaf, I. Polikparpov, M.C. Lima, S.L. Galdino, R.G. Brennan, J.D. Baxter, I.R. Pitta, P. Webb, K.J. Phillips, and F.A. Neves GQ-16, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, promotes insulin sensitization without weight gain J. Biol. Chem. 287 33 2012 28169 28179
125. A. Mieczkowska, M.F. Basle, D. Chappard, and G. Mabilleau Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism J. Biol. Chem. 287 28 2012 23517 23526
126. F. Wauquier, C. Philippe, L. Leotoing, S. Mercier, M.J. Davicco, P. Lebecque, J. Guicheux, P. Pilet, E. Miot-Noirault, V. Poitout, T. Alquier, V. Coxam, and Y. Wittrant The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation J. Biol. Chem. 288 9 2013 6542 6551
127. S. Wang, K.S. Awad, J.M. Elinoff, E.J. Dougherty, G.A. Ferreyra, J.Y. Wang, R. Cai, J. Sun, A. Ptasinska, and R.L. Danner G protein-coupled receptor 40 (GPR40) and peroxisome proliferator-activated receptor gamma (PPARgamma): An integrated two-receptor signaling pathway J. Biol. Chem. 290 32 2015 19544 19557
128. 12,14-prostaglandin J2 induces renal epithelial cell death through NF-kappaB-dependent and MAPK-independent mechanism Toxicol. Appl. Pharmacol. 216 3 2006 426 435
129. K. Takeda, T. Ichiki, T. Tokunou, N. Iino, and A. Takeshita 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells J. Biol. Chem. 276 52 2001 48950 48955
130. W.A. Wilmer, C. Dixon, L. Lu, T. Hilbelink, and B.H. Rovin A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPAR gamma Biochem. Biophys. Res. Commun. 281 1 2001 57 62
131. K. Kitz, W. Windischhofer, H.J. Leis, E. Huber, M. Kollroser, and E. Malle 15-Deoxy-Delta12,14-prostaglandin J2 induces Cox-2 expression in human osteosarcoma cells through MAPK and EGFR activation involving reactive oxygen species Free Radic. Biol. Med. 50 7 2011 854 865
132. J.H. Choi, A.S. Banks, T.M. Kamenecka, S.A. Busby, M.J. Chalmers, N. Kumar, D.S. Kuruvilla, Y. Shin, Y. He, J.B. Bruning, D.P. Marciano, M.D. Cameron, D. Laznik, M.J. Jurczak, S.C. Schurer, D. Vidovic, G.I. Shulman, B.M. Spiegelman, and P.R. Griffin Antidiabetic actions of a non-agonist PPAR gamma ligand blocking Cdk5-mediated phosphorylation Nature 477 7365 2011 477 481
133. D.K. McGuire, and S.E. Inzucchi New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications Circulation 117 3 2008 440 449
134. N. Mittal, and S.N. Sanyal Effect of exogenous surfactant on phosphatidylinositol 3-kinase-Akt pathway and peroxisome proliferator activated receptor-gamma during endotoxin induced acute respiratory distress syndrome Mol. Cell. Biochem. 361 1-2 2012 135 141
135. C. Liu, T. Feng, N. Zhu, P. Liu, X. Han, M. Chen, X. Wang, N. Li, Y. Li, Y. Xu, and S. Si Identification of a novel selective agonist of PPARgamma with no promotion of adipogenesis and less inhibition of osteoblastogenesis Sci. Rep. 5 2015 9530
136. W. Zheng, L. Qiu, R. Wang, X. Feng, Y. Han, Y. Zhu, D. Chen, Y. Liu, L. Jin, and Y. Li Selective targeting of PPAR gamma by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency Sci. Rep. 5 2015 12222
137. C. Zhou, C. Tang, E. Chang, M. Ge, S. Lin, E. Cline, C.P. Tan, Y. Feng, Y.P. Zhou, G.J. Eiermann, A. Petrov, G. Salituro, P. Meinke, R. Mosley, T.E. Akiyama, M. Einstein, S. Kumar, J. Berger, A.D. Howard, N. Thornberry, S.G. Mills, and L. Yang Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists Bioorg. Med. Chem. Lett. 20 3 2010 1298 1301
138. C.P. Tan, Y. Feng, Y.P. Zhou, G.J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, T.E. Akiyama, M. Einstein, S. Kumar, J.P. Berger, S.G. Mills, N.A. Thornberry, L. Yang, and A.D. Howard Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice Diabetes 57 8 2008 2211 2219